153 related articles for article (PubMed ID: 36434945)
1. Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
Mysona D; Dorr K; Ward A; Shaver E; Rungruang B; Ghamande S
Gynecol Oncol; 2023 Jan; 168():114-118. PubMed ID: 36434945
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
Thomaier L; Darst BF; Jewett P; Hoffmann C; Brown K; Makaram A; Blaes A; Argenta P; Teoh D; Vogel RI
Gynecol Oncol; 2021 Dec; 163(3):578-582. PubMed ID: 34674889
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
4. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
[TBL] [Abstract][Full Text] [Related]
5. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
Wang YJ; Chan YN; Jheng YW; Wu CJ; Lin MW; Tseng LM; Tsai YF; Liu LC
Support Care Cancer; 2021 Jun; 29(6):2959-2971. PubMed ID: 33025227
[TBL] [Abstract][Full Text] [Related]
7. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial.
Lustberg M; Wu X; Fernández-Martínez JL; de Andrés-Galiana EJ; Philips S; Leibowitz J; Schneider B; Sonis S
Support Care Cancer; 2023 Jan; 31(2):139. PubMed ID: 36707490
[TBL] [Abstract][Full Text] [Related]
8. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the effect of lithium on taxane-induced neuropathy.
Kochan DC; Novotny PJ; Cathcart-Rake EJ; Orme JJ; Tevaarwerk AJ; Ruddy KJ; Childs DS
Support Care Cancer; 2023 Apr; 31(5):299. PubMed ID: 37097406
[TBL] [Abstract][Full Text] [Related]
10. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
[TBL] [Abstract][Full Text] [Related]
11. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
[TBL] [Abstract][Full Text] [Related]
12. Electroacupuncture use for treatment of taxane-induced peripheral neuropathy in patients with breast cancer: protocol for a pilot, randomised, blinded, sham-controlled trial (EA for CIPN).
Choi V; Park SB; Lacey J; Kumar S; Heller G; Grimison P
BMJ Open; 2024 Jan; 14(1):e076391. PubMed ID: 38195173
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
Kang YJ; Yoon CI; Yang YJ; Baek JM; Kim YS; Jeon YW; Rhu J; Yi JP; Kim D; Oh SJ
BMC Cancer; 2023 Jun; 23(1):570. PubMed ID: 37340369
[TBL] [Abstract][Full Text] [Related]
14. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
Johnson C; Pankratz VS; Velazquez AI; Aakre JA; Loprinzi CL; Staff NP; Windebank AJ; Yang P
J Neurol Sci; 2015 Feb; 349(1-2):124-8. PubMed ID: 25586538
[TBL] [Abstract][Full Text] [Related]
15. The use of vitamin E in preventing taxane-induced peripheral neuropathy.
Heiba MA; Ismail SS; Sabry M; Bayoumy WAE; Kamal KA
Cancer Chemother Pharmacol; 2021 Dec; 88(6):931-939. PubMed ID: 34468794
[TBL] [Abstract][Full Text] [Related]
16. Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy.
Khan Z; Jung M; Crow M; Mohindra R; Maiya V; Kaminker JS; Hackos DH; Chandler GS; McCarthy MI; Bhangale T
Genome Med; 2023 Jun; 15(1):45. PubMed ID: 37344884
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo.
Myftiu B; Hundozi Z; Sermaxhaj F; Blyta A; Shala N; Jashari F; Qorraj Bytyqi H; Hyseni E; Kurtishi I
Med Sci Monit; 2022 Aug; 28():e937856. PubMed ID: 36042691
[TBL] [Abstract][Full Text] [Related]
18. Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.
Wu S; Bai X; Guo C; Huang Z; Ouyang H; Huang J; Zeng W
BMC Cancer; 2021 Nov; 21(1):1173. PubMed ID: 34727879
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.
Bulls HW; Hoogland AI; Kennedy B; James BW; Arboleda BL; Apte S; Chon HS; Small BJ; Gonzalez BD; Jim HSL
Gynecol Oncol; 2019 Feb; 152(2):310-315. PubMed ID: 30558975
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Mukai H; Katsumata N; Sunada Y; Watanabe T; Hausheer FH
Support Care Cancer; 2009 Dec; 17(12):1483-91. PubMed ID: 19330359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
